XDH and chronic kidney disease: However, ongoing debate centers on whether the benefits of uric acid-lowering therapy stem from decreased uric acid levels or the inhibition of XO activity.319,324,325 Further investigations have shown that medications like benzbromarone and febuxostat can mitigate the advancement of chronic kidney disease and decrease serum uric acid levels in CKD patients, highlighting the potential advantages of treatments aimed at lowering uric acid levels.319,326–328